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INTRODUCTION
cphalO\portm consolUte about 5m~, of the aU p-betaJll
anahlotlcs. These denvativt'S can be divided into tour gcnl'r:\-
noDs (although omroversy ~ll rroulll.1.s the lassification of the
laurth): the fim olle in ludes compound.s u h . s ccfa.z lUI or
cephalexm: cefurmQme. ccL1c1oT. CefOXltlD and cefotccall an.:
example<; of second-generation cephalosponru; the denvative
corlt:unmg l11erhoxumJ]o subsntucnts such ccfot:lX1llle,
cefrrtaxonc and c<.1tazldsntc belong t the dmd; while the
taurth genel'2DOn includes cefcpil1le and efpirome. The firsl
gene tion IS very anive agair t Gr:ull-p<>sitive org;lnisl1t~ and
susccpoble to ll-betamase ctivity. rhe tlmd is very active ag.linst
,ram-negative rod5 and !ughly reSIStant t enzymatic hydrolYSL~
and dIe fourth 15 very active agalllsl both Gram-positive and
n~Dve strains. tncluding PSl'l/dOIl/ClI/(lS (len/gil/ostl.
A c mbm. ti n of three tlcton d('tennincs Uti.' antimicrobial
ctlvity ofcephal ~POrill : penetration rate, p-laCf.1I1laSe sLlScept-
Ibl1ity and pct1ldllin-btnding pr tems (PBp ) IIlhibllioll. There
IS an lnlertelanonship among thes • rhree: (1 'tors and pcn.err:loon
rate m:sy be unponallt for . m-neg;ltive bartcna.
The penetrnrion into Gram-negative rod dcpend~ on the
hydrophobicity. the charge ,nd the molccul. r weight of the
compound. ince rhe outer membrane prins ( mp) prefer
small hydrophilic molecules and better c cioni deriv. tiv [I].
ephalosponns have phy icochemicaJ properties related to
thel.r IOniC pol.lricies which determine thcir 1ll11lnly hydrophilic
nature. thus condicioning their . ntisnicrobi. I specccum of
acovllY and od st:lbsLty [21.
mcc rhree facton affect p-Iacram penerration of the
extcmal membrane (hydr phobi ity. molecular size ,nd
charge) :I different clas ification c. n be pr posed for
~-laCta11U ba ed on tlleir p larily. efazo!in, cfuroximc,
cefoniod and latamoxef are examples of monopolar and
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dipol. r anionic compounds and onsistcmly diffuse less wdl
than ZWltleriomc deriv. tlves IIllO Gram-neg;Jove rods.
Dipobr cephem den\' rives (i.e. ce aclor. ccfotaxime nd
cefecamct) usually pcnetrare rcadily imo the bactl'rial
pcripltlsrni space. ~ Itile trtpol. r dic tionic compounds such
as cefplromc Jnd cefepime (i.e. the fi urth-generation
cephalosporins) and rett'3polar nes. not. bl c~rrnzidimc.
show very high penetration rates [21.
We have determined rhe penetr.lti n rate of dilTerem
parellh:ral ccphalosponm tnto dim al i olates of ,ram-
ncgarive r ds wirh nomul porin hanJlcl~. constitutively
pro tll ing. la ~Ia mase, using. pectrophorometri
method in intact (clJs [3]. The preliminary results of thi.~
resear It con6ml this behavior. n r only n Esrlrrrirlrill roli. but
also III other enterobacteria (Figures 1 nd 2) 14]. As a matter of
fact the oureh-generatlon cephalosporins . nd cefta.zidime arc
among rhe comp unds with the highesr penneability oeffi-
cil·11t ~ r ,r31l1-negative rod.\ [2,41.
Another Import:lllt a~pe t is due to the F.t t rhat rhe varying
levels of affinity or rhe different PBPs detemline the spc trulll
of • crion. rhe bactencidal rate alld the ill lIilro and ill 1';110
antimicrobial acnvlty of l3-1acrnn .
However, rhe efficacy of 31ltimicr bjal rherapy does not
relate olely t indices of ill vilro anlim.icr bial a civity u h a.~
minimum inhjbitory concentration (MI 'j . nd Illinimlln
b:scrcricidal concentrntion (ME ), but al 0 to rhann cody-
namlcs. An example is given by the posmntibiotic elfeo
(pAE). wlllch is rhe pef';istcnt suppression of b. terial growth
a ter lisnitcd exposure to an anti01l robi J agent [51. Artention
has recendy been given ro rills phen menon s a po ihlc
p. rarnctcr for rhe derc:m:tioation f m optimal d ,ing interval
r61. p-Iacrnms re time-dependem dru~ and therefore they
need t m. incain concenrrntions abo e dle MI s for a
relatively long time period t be SlICCCS ful. These antibiotics
do not Ita e t rge !'AEs. although mey may show some pAE
against ram-po itive trains, nd should bc administered \vith
hore intcrv:tls r In orne cases evcn by c ntinuous infusi n
[51. Ncvenhclcs differcnt ccphalosp rins m, y exert a
COil entration-dc:pendenc PAE. b th in vilr and ill vivoalso
for 'I'3m-neg:ative padlogem (Table I) 17-11]. However,
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Figure 1 Mean pe,moabliity coelf,c,onl (P. nm/s) of five cephalos-
por inS In iI K pnelJlr10nmc lrillO
Figure 2 Moan pe,meabihty coeffrcient (P. nm/s) of I,vo cephalos·
porlns in an E ClORCRO strilll1
Table 1 Mean m vitrO PAEs (hours) of oral and parenleral cephalosporlns agamSI Gram-posilive and Gram.negat,ve beclolill
Cephalosporin S. Pvogenes S. pneumoniBe S. aureus E. coli K. pneumoniae
Cefaclor 20 16 11
Celuro..me 31 1.3-35 14 1 5 0.97
CefolBxime 1 3-2.7 1 4 1.0-17
Cohazld,me 1.3--4.1 2.1-2.3 1.6-30





Organisms exposed 10 4-16 >. M IC (or 1-2 h Ma,nly v,able plate cou nI melhod 'PAE on B cepac/a 1.3 h r7-14]
cep11:l1(l~ponI1S s~elll 1111. ble to produCt: a consistt:nt PA' on
P l'lfd"llltJII'1 ~l'.
A pm~iblt: cxplan~ti n IS rdated to the r.lct that the PAE f
r3-lact~Ill' IS gellcr~jly ob\ervcd when th" prt:v31c1ll Illorphol-
n~ of the exposcd bacteria onSISts of spheropbst~.
A p-l3ctam . u.:h as azttcon. III that has J high activtly for
P13P3 product\ filamcnts, and IIsually has J relarively low PAE
that i cnnc"nrranon illdepcndcfft. H wcver, compounds al. 0
bindlll!-\ to othcr PBP~ (such as carbapenel11s and SOllie
cephalosporim) and allo atraimng SUfticiendy high cOllcemra-
tlons, produce sl'hcropbsts and IrHlger PAE [9]. FUrthcr. it
secn~ lhat the tlll1e-dependcfll kilhng activity of p-Ianams is
partially related to d1t' con ClluanOIl ( ) aclllcved at the me of
infecl'lon and usually with a IMI ratto equal or lughcr lhall
10 wc nl"erve a f.l'ter killing rate ItS. lui· Indecd. In SOlllt: ca. CoS
(e.g. ome P. ,u.,,~~i''''SIl isoLlte) the maximum bJcteri Kial
activity L\ observed wllh vay high IMI ranos (fahle 2) 191.
In conclusIon. when choosing a p-Iactam for therapeuri
lISC. their differcnt physicochemical . lid phamlacod~rnamic
charactensllcs must bc considered. In addition. although p-
Iacrams might have unrc~olved thcrJpcUIJC problcms in tern IS
of phanl1l1 odynami s. ph. nn. colunetics and imlllunogcm-
city. ccphalosporins, more: tlnn pcnicillins. have cOllle c10scr
to fulfilling the appropnate criteria. thus justifying their a tual
prevalen e 111 rhe 13-lactalll group.
Table 2 C/MIC rallO-eftecl relallonshrp of cellaz,d,me on
Pseudomonas aeruginoS8 ,solates from cystic fib'os's palm",s
Organism C/MIC for En,•• C/MIC for E90
------







Numbe,s rn pa,enlheses are Ihe number of strains Em•• - maximum
achievable killing effect E90 - 90% of E...... I. 16)
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